GOSS News and Press, Gossamer Bio Inc. From 04/25/22

Gainers: Nkarta (NKTX) +84%. ERYTECH Pharma (ERYP) +54%. Sunshine Biopharma (SBFM) +25%. Rubius Therapeutics (RUBY) +17%. Quoin Pharmaceuticals (QNRX) +12%. Losers: Eliem Therapeutics (ELYM) -55%. Clarus Therapeutics Holdings (CRXT) -54%....

Gossamer Bio (NASDAQ:GOSS) has lost ~9% in the pre-market Monday after the clincal stage biotech said that its Phase 2 study for GB004 in mild-to-moderate active ulcerative colitis (UC) did not meet the primary or secondary endpoints at week 12. The 236-patient trial was designed to...

— Study did not meet primary or secondary endpoints at week 12 — — GB004 Phase 2 SHIFT-UC Study to be terminated for lack of treatment benefit — — Target enrollment reached in Phase 2 TORREY Study of seralutinib in PAH; to...

Gossamer Bio [[GOSS, +8%]] was initiated with a Buy at UBS with a price target of $19. UBS said it thinks Gossamer's (NASDAQ:GOSS) clinical portfolio is underappreciated with near-term upside in 2022. The firm said Gossamer's has three programs — GB004 for ulcerative colitis ...

Gossamer Bio press release (NASDAQ:GOSS): Q4 GAAP EPS of -$0.74 misses by $0.02. Cash, cash equivalents and marketable securities totaled $325 million at year-end 2021. For further details see: Gossamer Bio GAAP EPS of -$0.74 misses by $0.02

Gossamer Bio (NASDAQ:GOSS) has filed for a mixed shelf offering of a yet to be determined amount. The filing does not necessarily indicate that a sale has begun, or will occur in the future. The company said use of proceeds will be explained in a prospectus supplement. The offering can i...

- GB004 topline results for the Phase 2 SHIFT-UC study in mild-to-moderate UC expected in the second quarter of 2022 - - Seralutinib (GB002) topline results for the Phase 2 TORREY study in PAH expected in the second half of 2022, subject to developments in the ongoing COVID-19...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will report its fourth quarter and full-yea...

Gossamer Bio, Inc. (GOSS) Q3 2021 Earnings Conference Call November 08, 2021, 16:15 ET Company Participants Bryan Giraudo - COO & CFO Faheem Hasnain - Co-Founder, CEO, President & Chairman Richard Aranda - Chief Medical Officer Conference Call Participants Yasmeen Rahimi - Piper Sandl...

Gossamer Bio (NASDAQ:GOSS): Q3 GAAP EPS of -$0.80 misses by $0.02. Cash, cash equivalents and marketable securities totaled $366 million as of September 30, 2021. Press Release For further details see: Gossamer Bio EPS misses by $0.02